Key result
Cardioneuroablation shows ~13% recurrence in refractory vasovagal syncope, emerging as a promising pacemaker-sparing strategy.
Why the study?
Does 3D mapping-guided cardioneuroablation prevent syncope recurrence in young patients with refractory cardioinhibitory vasovagal syncope?
Does 3D mapping-guided cardioneuroablation prevent syncope recurrence in young patients with refractory cardioinhibitory vasovagal syncope?
Cardioneuroablation is highlighted as a promising pacemaker-sparing strategy for refractory cardioinhibitory vasovagal syncope, though long-term recurrence data remain limited.
Answers are grounded in this paper and cite their sources.
May spare pacemakers in refractory cardioinhibitory vasovagal syncope; leaves long-term durability open.
Cardioinhibitory vasovagal syncope (VVS) refractory to pharmacotherapy poses a significant therapeutic challenge in young patients, for whom permanent pacemaker implantation carries substantial long-term risks. Cardioneuroablation (CNA) — catheter-based selective denervation of cardiac parasympathetic ganglia — has emerged as a promising pacemaker-sparing strategy [1]. An updated meta-analysis of 37 studies and 1,585 patients reported an overall syncope recurrence rate of 12.5% [2]; however, median follow-up across included studies often does not exceed 12 months, and long-term recurrence data remain limited in scope.
No takes yet. Share an insight, caveat, or question.
NGUADI et al. (2026) studied Refractory cardioinhibitory vasovagal syncope. 3D Mapping-Guided Cardioneuroablation was evaluated. Cardioneuroablation for refractory cardioinhibitory vasovagal syncope is a promising pacemaker-sparing strategy, with a cited meta-analysis of 1,585 patients reporting a 12.5% recurrence rate.
Synapse has enriched 10 related papers. Consider them for comparative context: